Sanara MedTech Inc. (SMTI) Fair Value 2026

SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-07-15, Sanara MedTech Inc. (SMTI) trades at $24.52, approximately 2258% above CirclFi’s Bayesian DCF fair value of $1.04. QOC: 6.5/10. Value Trap Risk: 18/100 (SAFE). 11/13 models active.

Key Facts

Ticker
SMTI
Price
$24.52
Quality Score
6.5/10
Value Trap Risk
18/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +95.1% upside with 55% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Sanara MedTech Inc. (SMTI) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Sanara MedTech Inc. (SMTI) appears overvalued as of : the median of 11 independent fair value estimates is $13.79, 43.8% below the current price of $24.52. Estimates range from $0.50 to $47.84. SMTI scores 6.5/10 on fundamental quality and 18/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Sanara MedTech Inc. Stock in 2026? →

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($24.52)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
$1.04 -95.8%
Earnings Power Value
Medium Conviction
$35.07 +43.0%
CUCE Ensemble
Low Conviction
$18.69 -23.8%
First Chicago
High Conviction
$47.84 +95.1%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Sanara MedTech Inc. (SMTI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Sanara MedTech Inc. at its current price of $24.53. The composite intrinsic value is estimated at $17.24 (-29.7% average return), with 8 models flagging overvaluation risk. Model dispersion is worth noting: First Chicago targets $47.84 (+95.1%), versus ML-RIV at $0.50 (-98.0%). This +193.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About SMTI?

11 of 13 models are currently active for SMTI. Of these, 2 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates SMTI's intrinsic value at $1.04, implying -95.8% downside from the current price. See which stocks rank higher →

How Does SMTI Rank in Orthopedic, Prosthetic & Surgical Appliances & Supplies?

Among 25 Orthopedic, Prosthetic & Surgical Appliances & Supplies stocks, SMTI ranks #14 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

Sanara MedTech Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is SMTI a Value Trap?

CirclFi's Value Trap algorithm assigns SMTI a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Sanara MedTech Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Sanara MedTech Inc.'s fundamental quality profile registers 6.5/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +193.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SMTI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SMTI's 11 active models, average confidence is 39%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sanara MedTech Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Orthopedic, Prosthetic & Surgical Appliances & Supplies Stocks Should You Also Analyze?

8 related Orthopedic, Prosthetic & Surgical Appliances & Supplies stocks with 13-model coverage

Read investment analysis: STE · ISRG · EW · MSA · CDRE

Frequently Asked Questions About Sanara MedTech Inc.

What is Sanara MedTech Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Sanara MedTech Inc. (SMTI) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.04. The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SMTI overvalued or undervalued right now?

At $24.52, 2 of 11 active models suggest SMTI may be undervalued, while 9 indicate potential overvaluation. The median of all 11 fair value estimates is $13.79, 43.8% below the current price of $24.52 — a consensus view that SMTI is overvalued. The assessment depends on which methodology best fits Sanara MedTech Inc.'s business model in Orthopedic, Prosthetic & Surgical Appliances & Supplies.

What does a Quality of Company score of 6.5 mean for SMTI?

Sanara MedTech Inc.'s QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SMTI?

CirclFi analyzes SMTI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is SMTI a value trap in 2026?

Sanara MedTech Inc.'s Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Sanara MedTech Inc. (SMTI) has a median fair value of $13.79 — 43.8% below the current price of $24.52 — as of 2026-07-15.” Source: circlfi.com/stock/SMTI/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on SMTI.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access